[A21-38] Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2021
Project no.: A21-38
Commission: Commission awarded on 01.04.2021 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Immune system and infections
COVID-19 in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)
Adult patients with low-flow oxygen (LFO) at start of treatment: indication of considerable benefit.
Adolescent patients with low-flow oxygen (LFO) at start of treatment: added benefit not proven.
Patients with high-flow oxygen (HFO)/non-invasive ventilation (NIV) at start of treatment: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.